“With the more contagious delta variant now dominant in the U.S. despite the widespread availability of vaccines, the need for effective treatments is once again growing more urgent.”
Shares of the relatively unknown biopharmaceutical company discussed in today’s article have experienced extreme volatility this month, hitting their all-time low on June 2nd before proceeding to soar to their all-time high on June 10th.
What are the most affordable biopharmaceutical growth stocks in the S&P 500 right now? Or, as today’s article puts it, which biopharma stocks in the… Read More »“The Most Growth, At The Cheapest Price”
Small- And Mid-Cap Biotech Picks For 2021 and holdovers from 2020.